Moderna to Pay Up to $2.25B to Settle Patent Suit Over Covid-19 Vaccine Technology
Frank Vinluan / medcitynews - Under the settlement, Genevant Sciences and Arbutus Biopharma will grant Moderna a non-exclusive license to their lipid nanoparticle technology for mRNA delivery in infectious disease vaccines. If Moderna’s full financial payout to the companies is reache…
AI Summary: Moderna has agreed to settle long-running patent disputes over its COVID-19 vaccine technology for up to $2.25 billion, resolving litigation with several claimants. The deal provides Moderna with broad licensing rights and clears a major legal uncertainty, allowing the company to move forward without another courtroom cliffhanger.
Servier Boosts Presence in Rare Cancers With $2.5B Acquisition of Day One Biopharma
Frank Vinluan / medcitynews - Day One Biopharmaceuticals is Servier’s biggest acquisition yet, topping the $2.4 billion it paid to buy Shire’s cancer business in 2018. Day One markets Ojemda, approved for treating pediatric low-grade glioma, the most common type of brain cancer in chi…
AI Summary: Servier is buying Day One Biopharmaceuticals for about $2.5 billion to bolster its rare oncology portfolio, gaining access to promising targeted therapies. The deal expands Servier’s presence in specialty cancer medicines and aligns with its strategic push into rare tumors, with integration and regulatory steps expected to follow.
FDA vaccine chief to step down in April
Ella Jeffries / beckershospitalreview - Vinay Prasad, MD, the FDA’s top regulator of vaccines and cell and gene therapies, will step down at the end of April, an agency spokesperson confirmed to Becker’s. Dr. Prasad joined the agency in 2025 on a one-year sabbatical from the University of Calif…
AI Summary: Vinay Prasad, the FDA’s top regulator for vaccines and cell and gene therapies, will step down at the end of April amid mounting criticism over controversial decisions that reportedly overrode agency scientists and spooked stakeholders. His exit follows prolonged internal and external disputes about regulatory judgment and leadership style.
AI blood test finds silent liver disease years before symptoms
sciencedaily - Researchers created an AI-driven liquid biopsy that scans patterns in fragments of DNA circulating in the blood. The system detected early liver fibrosis and cirrhosis—conditions that often go unnoticed until serious damage occurs. By analyzing genome-wid…
AI Summary: Researchers unveiled an AI‑driven liquid biopsy that scans genome‑wide cell‑free DNA fragment patterns to flag liver fibrosis, cirrhosis and chronic liver disease well before symptoms appear. Early results indicate the test can identify disease signals years ahead of clinical diagnosis, offering a shot at much earlier intervention — if practice and payers cooperate.
Groundbreaking new drug shows promise for treating children with a devastating form of epilepsy
livescience - An experimental treatment reduces seizures and other symptoms in children with a type of epilepsy called Dravet syndrome.
AI Summary: An experimental treatment markedly cut seizures and eased symptoms in children with Dravet syndrome, offering families dramatic improvements where few options existed. Early clinical data show promising safety and efficacy signals, but researchers caution larger, longer trials and regulatory review are needed before this becomes a routine option.
Novo Nordisk inks $2.1B oral obesity drug deal
Ella Jeffries / beckershospitalreview - Novo Nordisk has partnered with Vivtex Corp. to develop next-generation oral biologic medicines for obesity, diabetes and related conditions. Under the agreement, Vivtex will license its proprietary oral drug-delivery technologies to Novo Nordisk and is e…
AI Summary: Novo Nordisk has struck a multibillion‑dollar deal with Vivtex to develop next‑generation oral biologic therapies for obesity and related metabolic diseases. The partnership funnels major R&D resources into oral delivery technology, signaling the company’s bet that pills — not injections — will be the next commercial battleground in weight‑loss medicine.
Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours
esmo - Findings from the PYNNACLE study
AI Summary: Clinical results from the PYNNACLE program demonstrate that rezatapopt, an oral small‑molecule p53 reactivator, produces antitumor activity in cancers driven by the TP53 Y220C mutation. Early data validate targeting a previously “undruggable” p53 variant, offering a concrete therapeutic strategy and sparking excitement — and a few warranted caveats — about broader applicability.
Novartis closes Avidity deal as rare heart disease spinout launches
Lei Lei Wu / endpoints - Atrium Therapeutics launched Friday morning as Novartis closed the $12 billion deal to buy Avidity Biosciences and its RNA muscle therapies. The spinout will take on Avidity’s early-stage programs for genetic cardiomyopathies — heart muscle diseases ...
AI Summary: Novartis completed its Avidity Biosciences transaction and backed the launch of Atrium Therapeutics, a newly funded spinout focused on RNA therapies for rare cardiac conditions. Atrium inherits delivery platforms and early programs with substantial capital, as Novartis reshuffles assets to accelerate its RNA strategy — because apparently doubling down on hot modalities never gets old.
Merck Splits Oncology Business Unit as Keytruda Patent Expiry Nears
oncodaily - On February 23, 2026, Merck announced a reorganization of its Human Health structure into two business units: an Oncology Business Unit and a Specialty, Pharma & Infectious Diseases Business Unit. […]
AI Summary: Merck reorganized its Human Health structure to form a separate oncology business unit, positioning the company to defend and optimize its cancer franchise ahead of Keytruda patent pressures and to sharpen focus across therapeutic areas as part of a broader commercial realignment.
First-ever in-utero stem cell therapy for fetal spina bifida repair shows safe results
medicalxpress - A Phase I clinical trial published in The Lancet has shown that combining stem cell therapy with standard fetal surgery before birth is a safe and promising approach to treat myelomeningocele, a severe form of spina bifida. This is the first time live ste…
AI Summary: A Phase I study reports that adding stem‑cell therapy to standard fetal surgery for spina bifida is safe and may reverse fetal brain damage. Early clinical results published in a leading journal show feasibility and encouraging biological effects, setting the stage for larger trials and cautious optimism among researchers and clinicians.
Boehringer wins accelerated approval for first-line use of lung cancer drug
Lei Lei Wu / endpoints - The FDA greenlit an expanded label for Boehringer Ingelheim’s lung cancer drug Hernexeos, marking the first use of the Commissioner's National Priority Voucher for a new indication. Boehringer won an accelerated
AI Summary: Regulators accelerated approval of Boehringer Ingelheim’s lung cancer therapy for first‑line use, leveraging a priority review mechanism that sped the timeline. The label expansion places the drug into earlier treatment settings, reflecting promising data and the efficiency (and occasional controversy) of voucher‑assisted regulatory pathways.
Novartis to build $23B radioligand therapy site
Ella Jeffries / beckershospitalreview - Novartis will construct a 46,000-square-foot radioligand therapy manufacturing site in Denton, Texas, as part of its $23 billion U.S. investment. The facility will be Novartis’ fifth radioligand therapy site in the U.S. and its first in Texas, according t…
AI Summary: Novartis announced plans to construct a 46,000‑square‑foot radioligand therapy manufacturing facility in Denton, Texas, part of a broader $23 billion U.S. expansion. The site aims to boost domestic production capacity for targeted radiopharmaceuticals, signaling Big Pharma’s bet that radioligand therapies will be a growth engine — and a lovely way to justify large real estate footprints.
Patient dies in MacroGenics' cancer study, FDA puts trial on hold
Max Gelman / endpoints - The FDA has placed a partial clinical hold on MacroGenics’ Phase 2 study in gynecologic cancers after one patient died and three others experienced life-threatening side effects, the company disclosed Tuesday. The patient who died ...
AI Summary: Regulators have imposed a partial hold on a Phase 2 gynecologic cancer trial after multiple serious adverse events, including one patient death and additional safety incidents. The pause mandates review of trial protocols and safety monitoring before enrollment can resume, highlighting the inherent risks when experimental therapies meet human biology.
Generate Biomedicines’ $400M IPO Puts AI Drug Discovery Back in Focus
oncodaily - Generate Biomedicines priced its U.S. initial public offering on February 26, 2026, selling 25 million shares at $16 each for gross proceeds of $400 million, with trading expected on the Nasdaq under […]
AI Summary: Generate Biomedicines priced a U.S. IPO at $16 per share, selling 25 million shares and raising about $400 million to advance AI-designed drugs — notably a less-frequent injection candidate for severe asthma. The offering renews investor appetite for AI-driven biotech and funds pivotal clinical work, while whispering about a lofty post-listing valuation.
Cancer blood test fails to catch disease earlier in major study
medicalxpress - A blood test designed to find cancer early did not work as hoped in a major new study, according to the company that makes it.
AI Summary: A large trial evaluating GRAIL’s multi‑cancer blood screening test failed to meet its primary goal of earlier cancer detection. The disappointing result casts doubt on the test’s clinical utility for population screening, sparks debate over marketing and clinical use, and prompts calls for clearer evidence before widespread adoption.
More Research, Less Cancer: £250m raised to transform the future of cancer research
Charlotte Mathé / cancerresearchuk - We’ve reached an incredible moment - £250m raised for our More Research, Less Cancer campaign. This milestone brings us more than halfway to our £400m goal and accelerates our mission to prevent, detect and treat cancer earlier and more effectively. The p…
AI Summary: The More Research Less Cancer campaign has reached a £250 million fundraising milestone to accelerate cancer research, support translational projects, and expand patient-focused initiatives. Donor momentum will underwrite discovery science and clinical translation, giving researchers more runway to turn promising lab findings into treatments patients might actually see.
FDA Launches Framework to Accelerate Individualized Therapies for Ultra-Rare Diseases 2026
oncodaily - The U.S. Food and Drug Administration (FDA) has released groundbreaking draft guidance introducing a new regulatory framework designed to accelerate the development and approval of individualized therapies for patients with […]
AI Summary: The FDA released draft guidance creating a regulatory pathway to speed individualized and N-of-1 cell and gene therapies for ultra‑rare diseases. The framework clarifies evidence expectations, manufacturing and safety-monitoring options, and trial design flexibility to help get bespoke treatments from bench to bedside faster — no miracles promised, just fewer bureaucratic speed bumps.
Gilead to acquire cell therapy manufacturer for $7.8B
Paige Twenter / beckershospitalreview - In a deal worth $7.8 billion, Gilead Sciences has entered a definitive agreement to acquire Arcellx, a biotech company developing a cell therapy for multiple myeloma. Gilead announced the acquisition agreement a few months after Arcellx published positive…
AI Summary: Gilead Sciences agreed to acquire Arcellx for $7.8 billion to secure manufacturing and commercialization of a leading multiple myeloma CAR‑T candidate. The deal folds Arcellx’s anito‑cel program into Gilead’s oncology portfolio, accelerating regulatory filings and scale‑up plans — because buying your way into cutting‑edge cell therapy apparently never goes out of style.
Perioperative Enfortumab Vedotin Plus Pembrolizumab Improves EFS, OS and pCR in Patients with MIBC Who Are Ineligible for Cisplatin
esmo - Findings from the KEYNOTE-905/EV-303 study
AI Summary: KEYNOTE‑905/EV‑303 results show perioperative enfortumab vedotin combined with pembrolizumab significantly improved event‑free survival, overall survival and pathological complete response in muscle‑invasive bladder cancer patients ineligible for cisplatin. The findings could shift neoadjuvant strategies for this high‑risk group and spur guideline updates and broader adoption in practice.
Data and Decisions in Advanced NSCLC at the 2026 TTLC Symposia – IASLC
oncodaily - International Association for the Study of Lung Cancer (IASLC) shared a post on LinkedIn: “2026 TTLC Symposia Event Data and Decisions in Advanced NSCLC The treatment landscape for advanced NSCLC is evolving […]
AI Summary: TTLC 2026 brought together lung cancer experts to present symposia on advanced NSCLC topics — from RAS inhibition to mechanisms of EGFR resistance — and unveiled new clinical data. The meeting, including LungCancerRx LIVE Season 2 sessions, fostered debate, rapid data exchange and collaborations likely to steer upcoming trials and treatment approaches.